| 
Did You Know?
Six of the 10 most commonly used equine vaccines were developed
at the Maxwell H. Gluck Equine Research Center, including
those against equine rhinopneumonitis (rhino), equine viral
arteritis, strangles and influenza.)
The first test for the diagnosis of horses affected with
equine protozoal myeloencephalitis (EPM), a parasitic neurological
disease occurring in horses in the Western Hemisphere, was
developed by researchers at the Maxwell H. Gluck Equine Research
Center.
Further research into Equine Protozoal Myeloencephalitis
by scientists at the Maxwell H. Gluck Equine Research Center
spawned the development of the first FDA-approved medication
available for treating the disease.
The first multivalent vaccine against equine influenza, a
viral respiratory disease which affects a large percentage
of the horse population each year, was developed at the Maxwell
H. Gluck Equine Research Center.
A group of Maxwell H. Gluck Equine Research Center scientists,
in collaboration with other University of Kentucky College
of Agriculture researchers, helped determine the cause of
the early fetal losses, late-term abortions and other problems
that occurred as a result of Mare Reproductive Loss Syndrome
(MRLS).
A Maxwell H. Gluck Equine Research Center scientist initiated
and was the first author of the “white paper”
developed in 2005 that led to full genome sequencing of the
horse by the National Human Genome Research Institute.
The first vaccine for Streptococcus equi (strangles) was
developed at the Maxwell H. Gluck Equine Research Center and
became commercially available in 1969.
In 1984, an epidemic of equine viral arteritis (EVA) enabled
Maxwell H. Gluck Equine Research Center researchers for the
first time to confirm existence of the "carrier"
state in stallions. This knowledge has been pivotal in devising
effective strategies for controlling the spread of EVA.
Since 1993, the Maxwell H. Gluck Equine Research Center has
been designated by the Office International des Epizooties
(World Organization for Animal Health) as a World Reference
Center for three significant equine viral diseases:
- Equine rhinopneumonitis
- Equine influenza
- Equine viral arteritis
In 1999, Gluck Center researchers were involved in the development
of a highly successful intranasal vaccine for equine subtype
2 influenza virus.
|
